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ABSTRACT
Nanoparticles and macromolecular carriers have been widely used to increase the efficacy of
chemotherapeutics, largely through passive accumulation provided by their enhanced permeability
and retention effect. However, the therapeutic efficacy of nanoscale anticancer drug delivery systems
is severely truncated by their low tumor-targetability and inefficient drug release at the target site.
Here, the design and development of novel L-peptide functionalized dual-responsive nanoparticles
(L-CS-g-PNIPAM-PTX) for active targeting and effective treatment of GRP78-overexpressing human
breast cancer in vitro and in vivo are reported. L-CS-g-PNIPAM-PTX NPs have a relative high drug load-
ing (13.5%) and excellent encapsulation efficiency (74.3%) and an average diameter of 275nm. The
release of PTX is slow at pH 7.4 and 25 C but greatly accelerated at pH 5.0 and 37 C. MTT assays
and confocal experiments showed that the L-CS-g-PNIPAM-PTX NPs possessed high targetability and
antitumor activity toward GRP78 overexpressing MDA-MB-231 human breast cancer cells. As expected,
L-CS-g-PNIPAM-PTX NPs could effectively treat mice bearing MDA-MB-231 human breast tumor
xenografts with little side effects, resulting in complete inhibition of tumor growth and a high survival
rate over an experimental period of 60 days. These results indicate that L-peptide-functionalized acid –
and thermally activated – PTX prodrug NPs have a great potential for targeted chemotherapy in
breast cancer.
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Introduction
Breast tumors, characterized by unlimited proliferation, is a
life-threatening disease with high morbidity and mortality
(Fan et al., 2017; Tiash et al., 2017). Conventionally, the disease
is clinically treated through chemotherapy and one of the
most successful compounds for the treatment of extensive
tumors (e.g. breast, lung, liver, kidney, etc.) (Tiwari et al., 2017)
is the diterpenoid, paclitaxel (PTX), mainly extracted from the
bark of the Pacific yew tree (Jiang et al., 2016). PTX has dem-
onstrated outstanding antitumor activity due to high-affinity
binding to microtubules, stabilizing and enhancing tubulin
polymerization, and as suppressors of spindle microtubule
dynamics (Wang et al., 2016; Zhang et al., 2018). Subsequently,
all those actions contribute to the suppression of cell mitosis,
motility and intracellular transport, which lead ultimately to the
apoptosis of carcinomas (Lin et al., 2017). Due to the above
properties, PTX has frequently been employed as a model
drug among a number of important chemotherapeutic agents
in recent cancer research (Yuan et al., 2015). However, most
antitumor drugs exhibit high-dose-limiting toxicities and
narrow therapeutic windows because of their poor specificity
and inadequate targeting ability (Zhang et al., 2017). Likewise,
in clinical trials, PTX causes a series of side effects, such as
hypersensitivity, myelosuppression, and neurotoxicity, and
many advances using PTX have been limited by its poor aque-
ous solubility (Kasala et al., 2017). Furthermore, the most detri-
mental aspect is that intravenous administration of PTX results
in drugs accumulating, not only in the lesion site but also in
other normal tissues, therefore, the selection of appropriate
carriers for drug delivery is particularly critical for the clinical
application of this antitumor compound (Pi et al., 2017). In
order to resolve these difficulties, nano-formulations have been
the focus of much research in order to improve the solubility
and targeting efficiency of PTX in the field of anti-tumor drug
therapeutics.
Among various PTX delivery systems, nano-scale biopoly-
mers hold numerous advantages (Bhirde et al., 2010; Madane
& Mahajan, 2016; Zhong et al., 2016; Huang et al., 2017),
including their ability to improve drug stability and pharmaco-
logical properties, offer enhanced longevity in the blood and
they provide an eligible carrier system that can protect and
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effectively deliver drugs to the target site by integrating differ-
ent treatment strategies into one platform in order to minim-
ize side effects. Specifically, compared with conventional
medicines, nanoparticle drug delivery systems are able to
exhibit passive/active target properties and controlled or sus-
tained drug-release kinetics (Xie et al., 2016). These nanopar-
ticles can also enhance the physicochemical properties of
drugs due to their enhanced permeability and retention (EPR)
effect and low cytotoxicity (Chen et al., 2016) as well as pro-
moting gradual apoptosis of distinctive carcinomas. For pas-
sive targets, it is notable that the observed tumor
environments are characterized by mild hyperthermia (1–2 C
above healthy tissue), acidic pH (lower than usual cellular pH)
(Canning et al., 2017) and excessive cell proliferation accompa-
nied by high enzymatic concentration compared to normal tis-
sues, which neutralizes the therapeutic efficacy of
administering the cytotoxic drug. Consequently, over the past
25 years, a great deal of research has concentrated on stimuli-
responsive polymers in order to obtain materials able to
respond to specific surroundings (Duan et al., 2011). These
drug delivery carriers are temperature- or pH-responsive, and
are frequently called ‘smart polymers’ (Zhang & Misra, 2007)
as they are able to undergo fast, abrupt, and reversible alter-
ation in their structure/properties in a response to small
changes in their surroundings. In order to improve and
increase their applicability, several smart polymers have been
developed to combine two or more mechanisms of respon-
siveness in only one platform. In the present study, the com-
bination of pH – and temperature – responsive properties
were generated by means of graft copolymerization of chito-
san (CS) with poly(N-isopropylacrylamide) (PNIPAM) so as to
carry out these dual-responsive functions concurrently. As is
well known (Chan et al., 2007), CS (2-amino-2-deoxy-(1 ! 4)-
b-D-glucosamine), which is obtained from chitin by deacetyla-
tion, is considered to be one of the most widely distributed
cationic biopolymers (Ding et al., 2017). It has good biocom-
patibility and biodegradability and has been used extensively
in the preparation of safe biomaterials. Chitosan nanoparticles
(CS NPs) offer numerous advantages making them promising
drug delivery materials (Hua et al., 2011). Due to their subcel-
lular and sub-micrometer size, CS NPs can penetrate deeply
into tissues, and pass through the fenestration present in the
epithelial lining (Hwang et al., 2008) and, above all, CS is sensi-
tive to variations in pH (Hashad et al., 2016). These factors
indicate that CS a perfect material for delivery of therapeutic
agents into the body. On the other hand, PNIPAM is widely
recognized as a thermal responsive polymer, since the lower
critical solution temperature (LCST) of PNIPAM is closer to
body temperature (Echeverria et al., 2015) and it undergoes a
volume transition in water upon heating above 32 C.
Additionally, PNIPAM is biodegradable, therefore, PNIPAM
modified CS has been synthesized as the dual-responsive poly-
mer for promising applications in the biomedical field. In this
paper, chitosan-graft-poly(N-isopropylacrylamide) (CS-g-
PNIPAM) NP was employed as a potential antitumor drug car-
rier that could respond to both temperature and pH simultan-
eously. In the past few decades, many grafting modifications
for the preparation of thermally sensitive CS materials, such as
living free radical nitroxide-mediated polymerization (NMP)
and atom transfer radical polymerization (ATRP) have been
reported, however, these polymerizations were not controlled.
In contrast, reversible addition fragmentation chain transfer
(RAFT) polymerization, which is a fast reversible process involv-
ing a thiocarbonyl compound reacting with propagating chain
radicals, may be a promising alternative (Tang et al., 2008). In
this study, the RAFT technique was employed to synthesize
CS-g-PNIPAM NPs.
However, to act as versatile platforms for cancer therapy,
the specificity of the nanoparticles toward tumors requires
further improvement. An optimal nanoparticle system should
have the ability to ‘turn off’ the internalization function dur-
ing circulation in the blood, but be ‘turned on’ when inside a
tumor. Recently (Chen et al., 2016; Wang et al., 2016), active
strategies using biological targeting moieties, such as pepti-
des, proteins, monoclonal antibodies, nucleic acid aptamers,
and other small molecules (Gao et al., 2009; Hu et al., 2011)
which bind to specific biomarkers on the surface of tumor
cells have been developed. In principle, these active target-
ing strategies involve modifying the surface of nanoparticles
with target molecules that can recognize and bind specific-
ally to the tumor cells (Goel et al., 2014; Shamay et al., 2016),
enhancing the ability of the nanoparticles to be transported
into the tumor cells from the extracellular space (Gao et al.,
2009, 2016; Goel et al., 2014). Peptide ligands provide a
promising prospect as an active target probe and are com-
monly discovered by selection from a random peptide library
using display technologies or from the sequences of the
binding proteins (He et al., 2017). Here a tumor-targeting
peptide was proposed previously (Lee et al., 2004), L-peptide
(RLLDTNRPLLPY), which was discovered through screening
phage-display peptide libraries on nasopharyngeal carcinoma
(NPC) cells is utilized. In addition, it is reported that
L-peptides might bind GRP78 (glucose-regulated protein 78, a
verified specific tumor surface marker as well as a promising
target for selective cytotoxicity of carcinomas) on the surface
of cancer cells (Wang et al., 2016) and L-peptide-linked lipo-
somes loaded with doxorubicin showed a higher efficacy for
tumor suppression than liposomal doxorubicin alone, and
apparently did not cause side effects in vivo (Wang et al.,
2016). Also, further investigation is required since GRP78
plays an anti-apoptotic role in excessive proliferative cells
(Chen et al., 2014), therefore, L-peptide decorated NPs may
regulate both pro-survival and pro-apoptotic signaling
pathways in tumors. In the present study, the L-peptide was
conjugated to the CS-PNIPAM NPs as a drug carrier, endow-
ing it with passive and active targeting properties simultan-
eously, and after loading this formulation with PTX,
employing it in breast cancer therapy (Scheme 1).
Subsequently, the stimuli-responsive behavior of this bio-
copolymer, the capacity of this peptide-functionalized NP to
target cancer cells, as well as the therapeutic efficacy of this
versatile formulation was examined. Moreover, on the basis
of the experimental results, considerable effort has been
made to achieve an optimal tumor-targeting effect, and to
offer the possibility of a viable breast tumor chemotherapy
regime to the clinician.
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Materials and methods
Materials
CS (degree of deacetylation >90%, Mw 200kDa) was obtained
from Sino Pharm Chemical Reagent Co., Ltd (Shanghai, China).
Azobisisobutyronitrile (AIBN), S-1-dodecyl-S0-(a, a0-dimethyl-
a00-acetic acid) trithiocarbonate (DDACT) and PTX were
purchased from the Aladdin Company (Shanghai, China).
Hoechst 33342 was obtained from the Keygen Biochemical
Company (Nanjing, China). N-Isopropylacrylamide (NIPAM),
fluorescein isothiocynate (FITC), N, N-dicyclohexylcarbodimide
(DCC), 4-(dimethyl-amino) pyridine (DMAP), 1-(3-dimethylami-
nopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl),
N-hydroxysuccinamide (NHS), 3-(4, 5-dimethyl-thiazol-yl)-2,
5-diphenyltetrazolium bromide (MTT), and phosphate buffered
saline (PBS) were purchased from Sigma-Aldrich (St. Louis, MO).
N, N-Dimethyl formamide (DMF) was distilled under reduced
pressure from calcium hydride and stored over molecular
sieves (4A). L-Peptide (RLLDTNRPLLPY) was provided by
Dangang Bio-Technology Co., Ltd. (Hangzhou, China).
Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum
(FBS), penicillin, streptomycin, and trypsin–EDTA were obtained
from Gibco (Carlsbad, CA). MDA-MB-231 cells and L929 cells
were purchased from the Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China). Deionized
water used throughout the research work was produced
using a Milli-Q Gradient A10 System. All other chemical
reagents were of analytical grade and used without further
purification.
Female nude mice (aged 4–6 weeks) were provided by the
Animal Center of Kunming Medical University (Kunming,
China). The animals were housed at 20–22 C with a 12:12 h
light/dark cycle. The protocol of the experiment was approved
by the Animal Care and Use Committee of Kunming Medical
University. All animal experimental procedures conform to the
Guide for the Care and Use of Laboratory Animals that was
published by the US National Institute of Health (NIH
Publication No. 8523, revised 1985).
Synthesis of L-peptide functionalized CS-g-PNIPAM NPs
The preparation of the PTX-loaded L-peptide functionalized
CS-g-PNIPAM (L-CS-g-PNIPAM-PTX) NPs was based on the
RAFT method (Tang et al., 2008), using the synthetic route
shown in Figure 1. Initially, in order to protect the NH2– func-
tionality, CS (5g) was dissolved in acetic acid (500mL; 1.0%)
containing acetic anhydride in the molecular ratio (1:0.4). After
the addition of absolute ethanol (500mL), the mixture was
stirred at room temperature under nitrogen and after 8 h of
reaction, the resulting mixture was poured into ice water. The
precipitate was then filtered, washed with of methanol
(150mL) and dried at room temperature for 1 h to obtain
N-acetyl CS. Subsequently, the CS-RAFT agent was prepared
according to the previously described procedure (Tang et al.,
2008). N-acetyl CS (0.29g) was dissolved in dry DMF (30mL)
and stirred for 48h at room temperature with DDACT
(1.0mmol) in the presence of DCC (1.0mmol) and DMAP
(0.12mmol). The resulting mixture was poured onto ice water,
the precipitate was filtered, then washed completely by
Soxhlet extraction with acetone and dried to give a yellow
powder (0.499g, 81% yield). A mixture of the CS-RAFT agent
(0.05mmol trithio groups) and dry DMF (5mL) was stirred
magnetically under argon atmosphere until completely dis-
solved. AIBN (0.0016g, 0.01mmol) and NIPAM (0.50g) were
added, the reaction mixture was heated to 60 C with stirring
for 24h and then the reaction mixture was poured into diethyl
ether (25mL) and the precipitate filtered to obtain N-acetyl
CS-PNIPAM NPs (0.0295g, 63% yield). The acetyl groups were
removed by stirring the N-acetyl CS-PNIPAM NPs in NaOH
solution (15.4 M) 48h at room temperature. Covalent binding
of the L-peptide (NH2-RLLDTNRPLLPY-COOH) was achieved by
first protecting the NH2 by acetylation and then linking this to
the NH2-CS-PNIPAM by activating with EDC/NHS (EDC 104mg,
NHS 68mg) solution for 30min and then adding the L-peptide
(14.28mg/mL, 1.5lL) to form a mixed solution which was
reacted under gentle stirring at room temperature overnight.
After hydrolysis of the N-acetyl group, the resulting mixture
was centrifuged at 11,000 rpm for 10min and washed three
times with DI water in order to remove any unreacted starting
materials. Finally, PTX-loaded NPs were prepared by the solv-
ent dialysis method whereby the freeze-dried L-CS-g-PNIPAM
NPs (100mg) and PTX (20mg) were dissolved in DMSO
(10mL), sealed in a dialysis bag with a 14,000Da Mw cutoff,
dialyzed for 48h at 25 C to remove any small molecules and
the resultant solution was centrifuged at 6000 rpm for 30min
to remove any un-encapsulated drug.
Drug loading and entrapment efficiency
As previously reported (Li et al., 2009, 2017), the amount of
encapsulated PTX was determined using the HPLC solvent
Scheme 1. Schematic illustration of the smart NPs with prolonged blood circu-
lation, enhanced tumor accumulation, efficient cancer cell uptake, pH- and tem-
perature-responsive release of PTX, and the capability of targeting breast
cancer cells.
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composition method. Briefly, L-CS-g-PNIPAM-PTX NPs (15mg)
were dissolved in the HPLC eluent and centrifuged at
6000 rpm for 15min; filtered through 0.22 lm membrane
filter; and the supernatant was analyzed for PTX by HPLC.
The percentage encapsulation efficiency (EE) and drug load-
ing (DL) were calculated as follows:
%EE ¼ ðPTXt PTXf=PTXtÞ  100
%DL ¼ ðPTXt PTXf=Total weight of nanoparticlesÞ  100
where PTXt is the total amount of PTX used in the prepar-
ation of NPs and PTXf is the un-encapsulated PTX present in
the supernatant.
Figure 1. (A) Schematic representation of synthesis of L-CS-g-PNIPAM-PTX NPs. (B) FT-IR spectra of CS, N-acetyl CS, CS-RAFT, and CS-g-PNIPAM. (C) 1H NMR spec-
trum of L-CS-g-PNIPAM NPs. (D) Representative SEM micrograph of L-CS-g-PNIPAM-PTX NPs; and (E) representative TEM micrograph of L-CS-g-PNIPAM-PTX NPs; (F)
evolution of the measured mean hydrodynamic diameters of L-CS-g-PNIPAM-PTX NPs using the tested range of temperatures.
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Characterization of NPs
Fourier transform infrared (FT-IR) spectra were recorded on a
Nicolet Nexus 670 spectrometer (Thermo Fisher, Waltham, MA)
by using powdered NPs (1mg) dispersed in KBr (100mg).
Scans were recorded over 3500–1125 cm1 with the resolution
of 2 cm1 and an average of 32 scans. 1H spectral measure-
ments were performed on a Bruker DRX 400 nuclear magnetic
resonance spectrometer (Bruker, F€allanden, Switzerland) using
D2O or d6-DMSO as solvent. The mean hydrodynamic particle
size and the polydispersity index (PDI) were measured by
dynamic light scattering (DLS, 90 Plus Particle Size Analyzer,
Brookhaven Instruments, Holtsville, NY). Zeta potential (ZP)
was measured by the same instrument equipped with a ZP
analyzer as previously described (Song et al., 2017). The par-
ticle size, PDI, and ZP were measured in triplicate. Particle
morphology was characterized with a scanning electron micro-
scope (SEM) (FEI Nova TM Nano SEM, FEI, Hillsboro, OR) and
transmission electron microscopy (TEM) (JEOL 2010F, Tokyo,
Japan) operating at 200 kV using an aqueous solution of the
sample (3mg/mL) dropped onto a carbon-coated copper grid
and air dried before TEM analysis.
In vitro drug release
In vitro release behaviors of PTX, as a model drug, from the
NPs were studied by a dialysis method (Yang et al., 2012).
When the pH-responsive property was studied, the lyophilized
PTX-loaded NPs (containing 1mg PTX) were added to PBS
(1mL; pH ¼7.4) or acetate buffer (1mL; pH ¼ 5.0) in a dialysis
bag (molecular weight cutoff: 8000–14,000Da), which was
then immersed in the same buffer medium (25mL) and mag-
netically stirred (100 rpm) at 37 C. At predetermined times, ali-
quots (1mL) were taken from the medium and replaced with
pre-heated buffer solution (1mL) to maintain a constant vol-
ume and the amount of PTX released was determined by
HPLC analysis as previously described. Likewise, in an attempt
to demonstrate the temperature-responsive structure changes
facilitating PTX release of this NP, analogous experiments were
performed in PBS (pH 7.4; 0.1 M) at 25 C and 37 C. Each
experiment was repeated in triplicate.
Cell cultures
Breast cancer cell line MDA-MB-231 and fibroblast cell line
L929 used in this study were cultured in 25mL flasks and
maintained in a humidified 5% CO2 incubator at 37 C, with
DMEM containing 100U/mL penicillin and 100 lg/mL strepto-
mycin and 10% FBS. All cells were sub-cultivated approxi-
mately every three days at 80% confluence using 0.25% (w/v)
trypsin at a split ratio of 1:5.
Western blot assay
MDA-MB-231 and L929 cells were washed and lysed in modi-
fied RIPA buffer supplemented with 1:100 (v/v) of the protein-
ase/phosphatase inhibitor cocktail (Solarbio, Beijing, China).
Insoluble material was removed by centrifugation at 12,000g
at 4 C for 30min. Protein was determined by a BCA commer-
cial kit (Sigma, St. Louis, MO) and an equal amount of total
protein (40 mg) was loaded per lane and separated on a 10%
SDS-PAGE. Proteins were then transferred to polyvinylidene
difluoride (PVDF) membranes. Primary antibodies were anti-
GRP78 (1:2000 dilution) and anti-b-actin (1:5000 dilution) anti-
bodies (Santa Cruz Biotech, Santa Cruz, CA). The secondary
antibody was a horseradish peroxidase (HRP)-conjugated anti-
rabbit or mouse IgG (1:5000 dilution; Santa Cruz Biotech,
Santa Cruz, CA). The membranes were detected by enhanced
chemiluminescence (Millipore, Burlington, MA) and exposed to
an X-Omat film (Kodak, Xiamen, China), developed and the
intensity of the immunoreactivity was measured by densitom-
etry using Image J software.
In vitro cytotoxicity assays
The cytotoxicity of the PTX-loaded NPs against the above-
mentioned MDA-MB-231 cell lines was assessed by using an
MTT assay, using L929 cell lines as control. MDA-MB-231 and
L929 cells were continuously grown in DMEM cell culture
medium supplemented with penicillin (100U/mL) and strepto-
mycin (100 mg/mL). Subsequently, confluent cells were col-
lected and seeded in 96 well plates at a density of 1 104
cells per well. After 24h, prescribed amounts of NPs (i.e. Taxol,
L-CS-g-PNIPAM, and L-CS-g-PNIPAM-PTX) at PTX concentrations
ranging from 0.001 to 10 mg/mL in 20 mL of PBS were added
and incubated in an atmosphere containing 5% CO2 for 4 h at
37 C, then the supernatant was carefully aspirated, and the
MTT-formazan generated by live cells was dissolved in DMSO
(150 mL) over 20min. Finally, the absorbance at 490nm was
measured using a microplate reader (MULTSIKANMK3, Thermo,
Waltham, MA). The cell viability (%) was determined by com-
paring the absorbance at 490nm with control wells containing
only cell culture medium. The experiments were performed
in triplicate.
In vitro cellular uptake
To verify the targeting capacity of L-peptide, cellular uptake
experiments were employed. The NPs were previously labeled
with FITC as follows: the CS-g-PNIPAM-PTX or L-CS-g-PNIPAM-
PTX NP (100mg) was dissolved in CH3OH, then the activated
FITC (40mg) was added to the mixture, which was stirred at
room temperature in the dark for 12h. The resultant mixture
was purified by recrystallization from acetone. The purified
CS-g-PNIPAM-PTX/FITC and L-CS-g-PNIPAM-PTX/FITC were
obtained as faint yellow powders in 68% and 75% yield,
respectively. The cell internalization study of L-CS-g-PNIPAM
NPs utilized L929 and MDA-MB-231 cells seeded at a density
of 1.0 104 cells per well on 18mm coverslips. After 24h of
incubation, the old medium was removed and fresh medium
(2mL) containing 200lL solution of CS-g-PNIPAM-PTX NPs or
L-CS-g-PNIPAM-PTX NPs (1mg/mL) was added. The medium
was discarded after 3 h, the cells were washed with PBS (pH
7.4) for 15min and the washing step was repeated twice.
Then, the cells were fixed with chilled methanol (–20 C) and
stained with Hoechst 33342 (1 mg/mL); the cells, were washed
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twice with PBS to remove excess dye; and the coverslips were
mounted on glass slides with glycerol. Finally, the fluorescent
images of the cells were observed using fluorescence micros-
copy (Nikon Eclipse Ti-S, Nikon Ltd, Tokyo, Japan).
The flow cytometry assay was carried out to verify the spe-
cific cellular uptake capacity of L-CS-g-PNIPAM-PTX NPs. L929
and MDA-MB-231 cells were inoculated into a six-well cell cul-
ture plate and co-incubated with 200lL CS-g-PNIPAM-PTX
NPs or L-CS-g-PNIPAM-PTX NPs (1mg/mL) for 4 h, respectively.
Meanwhile, the group co-incubated with PBS was used as con-
trol. Subsequently, all the cells in each plate were washed
twice with PBS, collected and the fluorescence intensity of PTX
in each sample was measured by flow cytometry.
Molecular level evaluation of apoptosis
Molecular level evaluation of apoptosis was performed by a
real-time reverse transcriptase polymerase chain reaction (RT-
qPCR). Three representative pro-apoptotic genes (Bax,
Caspase-3, Caspase-8) and one anti-apoptotic gene (Bcl-2)
were selected for determination at the messenger RNA
(mRNA) level. MDA-MB-231 cells (1 106 cells/mL) were har-
vested after being incubated with PBS, PTX, and L-CS-g-
PNIPAM-PTX for 48 h. The intracellular total RNA was
extracted using RNeasy Plus Mini Kits (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions and
random primed cDNAs were generated by reverse transcrip-
tion of total RNA samples with SuperScript II reverse
transcriptase (Thermo Scientific, Waltham, MA). Quantitative
real-time PCR was performed using the ABI Prism 7300
Sequence Detection System (Applied Biosystems, Foster
City, CA). The PCR mix contained cDNA (2 mL), of the
appropriate forward and reverse primers (1 mL) and
SYBR Green PCR Master mix (10 mL) (Roche, Basel,
Switzerland) in a total volume of 20 mL. PCR consisted of 40
cycles of denaturation at 94 C for 30 s, annealing at melting
temperature (Tm) for 30 s and extension at 72 C for 60 s.
Primer sequences were designed as follows: Bax forward
primer 50-TCATGGGCTGGACATTGGAC-30 and reverse 50-GAG
ACAGGGACATCAGTCGC-30, Caspase-3 forward primer 50-CGG
CGCTCTGGTTTTCGTTA-30 and reverse 50-CAGAGTCC-
ATTGATTCGCTTCC-30, Caspase-8 forward primer 50-CTGGTCTG-
AAGGCTGGTTGT-30 and reverse 50-GTGACCAACTCAAGGGCTCA-30,
Bcl-2 forward primer 50-CAACATCGCCCTGTGGATGA-30 and
reverse 50-GGGCCAAACTGAGCAGAGTC-30, and b-actin forward
primer 50-CGGCGCCCTATAAAACCCA-30, and reverse 50-
CGCGGCGATATCATCATCCA-30 (Tm 60 C). The fluorescence
signal was harvested at the end of each cycle and the results
were analyzed by the 2–CT method.
Hemolysis study
An in vitro blood hemolysis study was performed in order to
determine the pharmacological safety of the L-CS-g-PNIPAM-
PTX NPs. Whole blood was harvested from Sprague–Dawley
rats and centrifuged at 1500 rpm for 15min to isolate the red
blood cells (RBCs), which were then washed three times with
cold saline (Zhang et al., 2016). Taxol (PTX in Cremophor EL
and ethanol, v/v 1:1), L-CS-PNIPAM and L-CS-g-PNIPAM-PTX
were serially diluted to different concentrations and incubated
for 30min or 120min at 37 C in a water bath. After incuba-
tion, intact RBCs were separated by centrifugation (1500 rpm
for 10min) and supernatant was collected. The amount of
hemoglobin release was determined by reading the absorb-
ance at 540nm in a microplate reader (MULTSIKANMK3,
Thermo, Waltham, MA). To determine 100% hemolysis, RBCs
were lysed with ultrapure water and the hemolysis ratio (HR,
%) was calculated relative to ultrapure water, whereas the
saline acted as a negative control. Lower than 10% of HR was
recognized as being biocompatible in this study.
In vivo antitumor efficacy of L-CS-PNIPAM-PTX NPs
The antitumor efficacy of the L-CS-PNIPAM-PTXNPs was eval-
uated in tumor-bearing xenografts. A total of thirty 6-week-old
female athymic nude mice were used in this experiment and
each mouse was subcutaneously injected with a suspension of
5 106 MDA-MB-231 human breast tumor cells in physio-
logical saline (100 mL). When the tumor volume reached
100mm3, mice were divided into three groups (n¼ 10) ran-
domly, and subjected to one of the following treatments: (a)
physiological saline, (b) free PTX (dissolved in DMSO), (c) L-CS-
PNIPAM-PTX (10mg PTX equiv./kg) via a tail vein every
seven days. The body weight and survival rate were recorded,
tumor growth was monitored for each tumor-bearing mouse
every other day. At the end of the experiments, the animals
were sacrificed, the tumors were removed, and subjected to
metrological analysis. The tumor volume was calculated by the
following formula: V¼ (LW2) 0.5, where L is the length
and W is the width of the tumor.
TUNEL and histological examination
To detect cell apoptosis and morphological changes in tumor
tissue, tumor tissues isolated from the xenografts were sliced
into thin sections and stained with a TUNEL apoptosis detec-
tion kit (EMD Chemicals Inc., Darmstadt, Germany). For histo-
logical examination, the samples were fixed with 4% formalin,
embedded with paraffin and sliced into thin sections which
were stained with hematoxylin and eosin (H&E) and observed
by an optical microscope.
Statistical analysis
All experiments were repeated at least three times. Data
are expressed as the mean ± standard deviation. Data were
analyzed for statistical significance using ANOVA followed
by Tukey’s post hoc test (SPSS 19.0; SPSS, Chicago, IL).
p Values less than .05 were considered to be statistically
significant.
Results
Synthetic route
As a prerequisite condition, required constitutional units are
essential for the reliable fabrication of smart multifunctional
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nanocarriers through controlled self-assembly of dual-responsive
block copolymers (Chen et al., 2016). In the present study, the
preparation of two kinds of functional monomers, including
pH-responsive CS and temperature-responsive NIPAM was the
initial starting point and the synthetic route is briefly illustrated
in Figure 1(A). The dual-responsive NPs of CS-g-PNIPAM were
obtained from the monomers of NIPAM and CS by RAFT
copolymerization in the presence of DDACT as a cross-
linking agent.
The preparation and characteristics of various kinds
of NPs
First, in order to prepare the CS-RAFT agent, the CS was suc-
cessively modified with acetic anhydride to protect –NH2
groups of the CS and, subsequently, N-acetyl CS was reacted
with DDACT in the presence of DCC and DMAP to afford the
CS-RAFT agent. NIPAM was then grafted onto the CS-RAFT
according to the previously described method (Hua et al.,
2008) and FT-IR and 1H NMR techniques were applied to con-
firm the identity of the synthesized copolymers. The FT-IR
spectra of original CS, the N-acetyl CS, the CS-RAFT agent
and the grafted CS-g-PNIPAM copolymers are shown in
Figure 1(B). The absorption bands at 1082 and 1032 cm1
can be ascribed to the C3–OH and C6–OH of the CS and it
can be clearly seen that the characteristic peaks of CS at
1597 cm1 (–NH2) have disappeared after the successful syn-
thesis of CS-g-PNIPAM. In comparison with the original CS,
the peak at 1719 cm1 (C@O) appeared for chitosan-RAFT
agent, while the absorption for the trithiocarbonate units
(1062 cm1) was not observed due to the overlap with the
strong absorption of CS between 950 cm1 and 1200 cm1.
For CS-g-PNIPAM, the characteristic peaks at 1454 cm1
(–CH3) and 1641 cm
1 (C@O) showed the presence of
PNIPAM, and their intensity was greatly enhanced in the case
of CS-g-PNIPAM. In addition, the copolymers showed new
absorptions at 1385 and 1368 cm1 compared with CS, sug-
gesting the presence of isopropyl groups in NIPAM. All these
results further demonstrated the successful synthesis of CS-
g-PNIPAM.
Furthermore, the successful introduction of NIPAM and
the L-peptide onto CS was verified by 1H NMR and the spec-
trum of L-CS-g-PNIPAM NPs (Figure 1(C)) displays the peaks
of the protons on the carbon of CS (at 3.00–4.00 ppm). It is
evident that the characteristic resonances of PNIPAM are
shown at 0.82–2.10 ppm and 7.80 ppm, suggesting that CS-g-
PNIPAM had been successfully synthesized by RAFT polymer-
ization using CS-RAFT agent. In addition, it should be noted
that the signals of the dodecyl chain of the RAFT agent over-
lap with the characteristic peaks of PNIPAM. Obviously, two
peaks (–CH–CH2) at 1.00–2.20 ppm, a peak (–NH–CH<) at
3.90 ppm and a strong methyl group peak at 1.10 ppm all
proved the existence of NIPAM. For the preparation of L-pep-
tide functionalized NPs, the N-acetyl groups were removed
from the CS-g-PNIPAM by hydrolysis, then EDC and NHS
were used to activate the –COOH group of the L-peptide
and form an active intermediate which was reacted with
the amine group of CS to form a stable amide bond to the
L-CS-g-PNIPAM NPs. Successful synthesis of the L-CS-g-
PNIPAM NPs was also confirmed by a 1H NMR spectroscopy
where new signals appear in the 1H NMR spectrum of L-CS-g-
PNIPAM due to the introduction of L-peptide (Figure 1(C)).
The peaks at 8.65 ppm are the typical characteristic signal of
aromatics in the L-peptide and indicate that the successful
combination of the L-peptide residue with the CS backbone
has occurred.
Since the copolymers of L-CS-g-PNIPAM can readily self-
assemble and easily encapsulate poorly soluble drugs (Zhang
et al., 2016). PTX was successfully loaded into poly L-CS-g-
PNIPAM NPs by physical incorporation. They self-assembled in
water, in the hydrophobic domains of the NPs, into core-shell
nanocarriers at room temperature and neutral pH (7.4), where
the water-insoluble CS segments collapse as the cores, and
the water-soluble PNIPAM segments form the corona shell.
HPLC analysis indicated that DL was 13.5% while EE was
74.3%, suggesting that the relative high EE and DL of L-CS-g-
PNIPAM NPs are suitable for delivery of antitumor drugs.
The physicochemical properties of the various kinds of
NPs are shown in Table 1. Interestingly, the cores of the PTX-
loaded NPs have some influence on particle size, as com-
pared to the blank NPs, PTX-loaded NPs particle sizes are
smaller indicating that after the introduction of the drug, the
hydrophobic interaction forces between it and the carrier are
enhanced resulting in decreased particle sizes. The sizes of
all the NPs are below 300 nm and have a narrow size distri-
bution (PDI <0.45), which is appropriate for tumor targeting
by the EPR effect, and they have a size distribution that is
suitable for intravenous administration (Song et al., 2016;
Zhong et al., 2016; Wang et al., 2017).
The morphologies of L-CS-g-PNIPAM-PTX NPs were investi-
gated by SEM and TEM (Figure 1(D,E)). TEM studies indicate
that each nanocarrier has a diffusive boundary outside its
solid core, revealing the hydrophilic PNIPAM corona struc-
ture, and the results also show the uniformly spherical
morphology of L-CS-g-PNIPAM-PTX NPs with a diameter
which is slightly smaller than that measured by DLS. This
may be caused by dehydration during the sample prepar-
ation. In addition, it is worth noting that the L-CS-g-PNIPAM-
PTX NPs are positively charged due to the residual amino
groups on CS backbones. It is well known that PNIPAM NPs
collapse upon heating showing a negative response to
temperature and this property is favorable for the stimuli-
responsive release of anti-tumor drugs (Echeverria et al.,
2015). In the present study, the evolution with temperature
of the measured hydrodynamic diameter (Figure 1(F))
indicates the coincident trend. These results confirm that
Table 1. Physicochemical properties of CS, N-acetyl CS, CS-RAFT, CS-g-
PNIPAM, L-CS-g-PNIPAM, and L-CS-g-PNIPAM-PTX, each value represents the
mean ± SD (n¼ 3).
Particle size
(nm)
Zeta potential
(mV) PDI DL (%) EE (%)
CS 201.5 ± 18.6 31.4 ± 2.8 0.343
N-acetyl CS 226.3 ± 18.3 15.2 ± 1.9 0.417
CS-RAFT 251.5 ± 21.7 14.1 ± 2.6 0.283
CS-g-PNIPAM 268.0 ± 20.9 13.9 ± 2.1 0.352
L-CS-g-PNIPAM 278.2 ± 23.5 19.0 ± 3.2 0.224
L-CS-g-PNIPAM-PTX 275.4 ± 21.0 18.8 ± 2.0 0.205 13.5 ± 0.9 74.3 ± 5.8
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L-CS-g-PNIPAM-PTX NPs still show thermosensitivity and swel-
ling ability, therefore, the synthesized NPs were suitable for
targeted drug delivery.
MTT analysis
An in vitro cytotoxicity study, utilizing an MTT assay, was per-
formed to demonstrate the anticancer potential of a series of
formulations in MDA-MB-231 breast cancer cell lines and
L929 control cell lines. Since PTX has immense potential and
is currently one of the drugs of choice for the treatment of
breast cancer (Zhang et al., 2016; Song et al., 2017) its effect-
iveness, using the L-CS-g-PNIPAM NPs system, was explored.
As indicated in Figure 2(A,B), MTT tests for blank nanocarriers
showed that an increase in the concentration of NPs was not
harmful to the survival of both MDA-MB-231 and L929 cells
with the cell viability being around 100%. Obvious cytotox-
icity of the nanocarriers was not found in the MTT test and
noticeable cytotoxicity was not observed after incubation
indicating that the biocompatibility of the L-CS-g-PNIPAM
was satisfactory. Interestingly, a clear positive correlation was
found between cell cytotoxicity (MTT) and concentrations of
free PTX and L-CS-g-PNIPAM-PTX. Moreover, there was an
obvious reduction in cell survival as the PTX concentration
was increased above 0.1 lg/mL in both the MDA-MB-231 and
L929 cells. It is worth noting that the cytotoxic effect of L-CS-
g-PNIPAM-PTX NPs was greatly enhanced in the MDA-MB-231
cells compared to the L929 cells and the viability of free PTX
incubated cells was lower than that of L-CS-g-PNIPAM-PTX
incubated cells in L929 cells compared to MDA-MB-231 cells
Figure 2. In vitro cytotoxic activities of the different formulations against (A) L929 cells; (B) MDA-MB-231 cells; and (C) the IC50 of different formulations against
L929 cells and MDA-MB-231 cells. Data are expressed as mean ± SD (n¼ 5), p< .05, compared with L-CS-g-PNIPAM group; #p< .05, compared with free PTX group.
The mRNA relative expression levels of (D) Bcl-2, (E) Caspase-3, (F) Caspase-8, and (G) Bax in MDA-MB 231 cells. Data are expressed as mean ± SD (n¼ 5), p< .05,
compared with PBS group; p< .01, compared with PBS group.
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at several concentrations. An important parameter to
quantitatively evaluate the in vitro anticancer effect of a for-
mulation is to calculate the IC50 values (Zhang et al., 2017).
This study resulted in an IC50 value of 1.83 ± 0.21 and
2.31 ± 0.32lg/mL in L929 cells for free PTX and L-CS-g-
PNIPAM-PTX, respectively, while on the other hand the values
were 8.47 ± 0.77 and 0.94 ± 0.10 lg/mL in MDA-MB-231 cells
for free PTX and L-CS-g-PNIPAM-PTX, respectively (Figure
2(C)). This significant (p< .05) variation in IC50 values could
be due to the higher uptake of the novel L-CS-g-PNIPAM-PTX
NPs by the cancer cell lines. These results all confirmed that
the L-CS-g-PNIPAM-PTXNPs were effective in killing these
tumor cells and may be promising in future cancer therapy.
Molecular mechanisms underlying L-CS-g-PNIPAM-PTX
NPs treatment-induced apoptosis
In order to investigate the effect of L-CS-g-PNIPAM-PTX NPs
on breast carcinoma apoptosis in depth, it was necessary to
perform molecular level evaluation. RT-qPCR was used to
detect the expression mRNA levels of several pivotal apop-
tosis-regulatory genes (Bax, Caspase-3, Caspase-8, and Bcl-2)
in MDA-MB-231 cells. The Bcl-2 (B-cell lymphoma/leukemia-2)
gene is one of the important proto-oncogenes and was the
first confirmed gene to be able to participate in anti-
apoptosis of cells and prolong cell survival (Yang et al.,
1997). The expression of Bcl-2 mRNA in MDA-MB-231 cells
after 24 h incubation with PBS, free PTX, and L-CS-g-PNIPAM-
PTX was investigated by fluorescence quantitative PCR. As
shown in Figure 2(G), compared with the PBS group, free
PTX and L-CS-g-PNIPAM-PTX significantly inhibited the
expression of Bcl-2 mRNA in breast cancer cells and pro-
moted the process of cancer cell apoptosis. In addition, the
decreased effect of L-CS-g-PNIPAM-PTX was greater than in
the free PTX. In contrast, the caspase-3, caspase-8 genes (two
members of the cysteine-aspartic acid protease family), and
Bax (the inhibitor of Bcl-2) were activated in the apoptotic
cells both by extrinsic and intrinsic pathways, and they were
overexpressed in MDA-MB-231 cells after incubation of free
PTX or L-CS-g-PNIPAM-PTX. As expected, the L-CS-g-PNIPAM-
PTX treated cells exhibited the maximum mRNA content of
these three pro-apoptosis genes among all groups (Figure
2(D–G)). The results revealed that the L-peptide functionalized
NPs had the potential of inducing apoptosis in tumor cells,
however, cell apoptosis is a complex process, regulated by
many genes and the apoptotic mechanism of L-CS-g-PNIPAM-
PTX at the molecular level needs further in-depth investigation.
Western blot analysis
The L-peptide (RLLDTNRPLLPY), discovered through screening
of a phage-displayed random peptide library, is reported to
bind specifically to GRP78, which has been verified as resid-
ing to surface cells of certain cancers. Moreover, the binding
capacity of the L-peptide to GRP78 has been finally validated
by in vitro binding to various cancer cells and in vivo tumor
imaging and therapeutic studies (Wang et al., 2016). In the
present study, L-peptide functionalized dual-responsive NPs
were designed and synthesized as a potential chemothera-
peutic agent to treat breast tumors. Therefore, the difference
in the GRP78 expression levels between malignant breast
tumor cells and normal cells required examination and
Western blotting assays were conducted to determine the
GRP78 protein levels in MDA-MB-231 breast and L929 control
cells. As shown in Figure 3(A), GRP78 protein was highly
expressed in MDA-MB-231 cells, but with little evidence of
expression in L929 cells, indicating that GRP78 could be a
binding site for L-CS-g-PNIPAM NPs in breast tumor therapy
and that the L-peptide was able to perform its active target-
ing properties through interaction with GRP78.
Uptake ability of different kinds of NPs in cells
To assess the cellular uptake and cancer-targeting ability of
L-CS-g-PNIPAM-PTX NPs, MDA-MB-231, and L929 cells were
cultured with the NPs (with or without L-peptide conjuga-
tion), respectively. NPs loaded with PTX was labeled with a
fluorescence probe (green) and the nuclei were stained by
Hochest 33342 (blue) and the movement and location of the
L-CS-g-PNIPAM NPs toward cells was visualized by fluores-
cence microscopy. Figure 3(B) presents the fluorescence
microscope images of cells after incubation with or without
L-peptide functionalized CS-g-PNIPAM-PTX NPs and indicates
that neither of the agents showed obvious fluorescence in
the nucleus of control L929 cells, but fluorescence did appear
around the nucleus in the cytoplasm. On the other hand,
while CS-g-PNIPAM-PTX NPs showed a weak green fluores-
cence intensity, the L-peptide functionalized NPs showed a
strong fluorescence intensity in the nucleus of MDA-MB-231
breast tumor cells. This indicated that the L-peptide conju-
gated or not conjugated NPs could enter cells more easily
with no special targeting effect in normal cells and they
could be readily extruded by the efflux protein on the cell
membrane surface, with little adverse impact on cells. As for
MDA-MB-231 breast tumor cells, the fluorescence intensity of
L-CS-g-PNIPAM-PTX NPs in the nucleus is much stronger
compared to CS-g-PNIPAM-PTX NPs, indicating that the
GRP78-targeted L-peptide helps the drug to be internalized
in cancer cells revealing a virtuous targeting ability.
Furthermore, some morphological damage in cells was
observed, and the amount of MDA-MB-231 cells is obviously
decreased, suggesting that GRP78-targeted L-peptide can
intercalate with DNA and is involved in cell apoptosis (Liu
et al., 2016). This different intracellular drug uptake behavior
can also be attributed to the fast drug release from L-CS-g-
PNIPAM NPs by pH-and temperature-triggered shell-shedding
in the acid and possibly the hyperpyrexial microenvironment.
To provide further evidence, flow cytometry assay was
utilized to determine the cellular uptake properties of the L-
CS-g-PNIPAM NPs. CS-g-PNIPAM-PTX and L-CS-g-PNIPAM-PTX
NPs were incubated with L929 cells and MDA-MB-231 cells for
4 h and then the cellular uptake of PTX was quantitatively
investigated by flow cytometry as shown in Figure 3(C).
No significant difference was observed between CS-g-PNIPAM-
PTX and L-CS-g-PNIPAM-PTX NPs incubated L929 cell lines,
though the fluorescence intensity of the L-CS-g-PNIPAM-PTX
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NPs treated group (mean fluorescence intensity: 54.68) was
significantly increased compared to the CS-g-PNIPAM-PTX NPs
treated group (mean fluorescence intensity: 20.08) in MDA-
MB-231 cells, which is consistent with the results of confocal
microscopic analysis. All these cellular uptake results demon-
strate that L-CS-g-PNIPAM NPs are able to deliver more PTX
into tumor cells due to the active targeted effect of the
L-peptide.
Controlled PTX release
The effect of environmental stimuli on the release of the
drug from L-CS-g-PNIPAM-PTX was studied by dialysis, by
incubating the self-assembled nanocarriers in buffers at
different temperatures (37 C, 25 C) and pH (5.0, 7.4).
Figure 4(A) shows the cumulative release of PTX over a
period of three days at pH ¼7.4 and pH 5.0, from the L-CS-g-
PNIPAMNPs and it can be seen that the drug release was
slow at pH 7.4 while it was accelerated at lower pH.
Interestingly, low release of PTX is observed under conditions
mimicking storage and transit over a 72 h period at neutral
pH (7.4) when the PTX is encapsulated inside an insoluble CS
core. By contrast, PTX is released at a remarkably enhanced
rate under acidic conditions mimicking a tumor pH (5.0) due
to the fact that the core-shell nanocarriers are reversed under
these conditions and the CS based copolymers are exposed
to acid degradation. After the initial rapid release phase, the
profile gradually plateaus with prolonged PTX release at a
Figure 3. (A) GRP78 protein expression levels in L929 cells and MDA-MB-231 cells. (B) Cellular uptake of CS-g-PNIPAM-PTX and L-CS-g-PNIPAM-PTX NPs measured
by confocal in L929 cells or MDA-MB-231 cells; (C) cellular uptake of CS-g-PNIPAM-PTX and L-CS-g-PNIPAM-PTX NPs measured by flow cytometry in L929 cells or
MDA-MB-231 cells.
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much slower rate. This is because of acid digestion of the
CS-g-PNIPAM conjugated chain segments that are buried
inside the PNIPAM cores during the transition, which grad-
ually become exposed to the surface of the PNIPAM cores
due to its immiscibility with PNIPAM and constant polymer
chain movement. Figure 4(A) also shows the significant
change in release of PTX from L-CS-g-PNIPAM NPs at different
temperatures. Within 72 hours, only about 62% PTX was
released from L-CS-g-PNIPAM NPs at 25 C, but at 37 C,
release of PTX was enhanced to 83%. The increased early
stage release rate at both 25 C and 37 C is due to the avail-
ability of unbound drug on the surface of the L-CS-g-PNIPAM
NPs. However, during the later stage, PTX release was
reduced at 25 C due to a stable hydrophilic segment of the
PNIPAM units on the nanocarriers. However, when the tem-
perature is increased to 37 C, the PTX release rate is
increased due to the collapse of the structure of copolymers
possibly due to temperature-induced structural modification
of the L-CS-g-PNIPAM NPs triggered by the phase transition
of the PNIPAM. Based on the release profile data, these pH-
and temperature-responsive drug carriers appear to be most
suitable for cancer treatment.
Blood compatibility
Although PTX is a very effective anticancer drug there still
exists the challenge of inherent toxicity and one of the major
aims of the current work was to address and attempt to
reduce the toxicity posed by PTX through use of a bio-
degradable polymer such as L-CS-g-PNIPAM. The pharmaceut-
ical application of the L-CS-g-PNIPAM-PTX NPs in vivo
depends on several characteristics, including safety, stability,
and blood compatibility since they are usually administered
via intravenous injection. The hemocompatibility of the NPs
was therefore investigated and the hemolytic curves for free
PTX, L-CS-g-PNIPAM NPs and PTX loaded L-CS-g-PNIPAM NPs
at different concentrations of PTX are shown in Figure 4(B)
(during the experiments, the concentrations of PTX in the
two formulations were kept the same and therefore the con-
centrations of L-CS-g-PNIPAM and L-CS-g-PNIPAM-PTX NPs are
different). The results suggest that free PTX causes extensive
damage to RBCs, while L-CS-g-PNIPAM and L-CS-g-PNIPAM-
PTX NPs showed dramatically lower levels of hemolysis, illus-
trating the excellent blood compatibility of L-CS-g-PNIPAM NPs
as well as their potential application as drug delivery carriers.
In vivo anti-tumor effects
Finally, the therapeutic performance of L-CS-g-PNIPAM-PTX
NPs using MDA-MB-231 human breast tumor-bearing nude
mice was evaluated. The mice were treated with L-CS-g-
PNIPAM-PTX or PTX (10mg PTX equiv/kg) every three days
after the tumors grew to about 100mm3 in volume and
physiological saline were used in the control group. Thirty
days post-injection, the tumor size of mice treated with
saline was substantially larger with an average volume of
289.9 ± 32.9mm3 and average bodyweight of 19.1 ± 2.0 g
(Figure 5(A,B)). PTX treatment succeed in postponing the
growth of tumor tissue and the tumor body average volume
and weight were 142.7 ± 7.6mm3 and 17.9 ± 1.4 g, respect-
ively, which is about half of that for the saline-treated mice.
Strikingly, the average tumor size of L-CS-g-PNIPAM-PTX-
treated mice was statistically significant and much lower
than that of PTX-treated mice with an average tumor volume
and body weight were 51.7 ± 5.0mm3 and 20.5 ± 1.7 g,
respectively and significantly, the treatment had little adverse
effect on the mice physiology. Consistently, the treatment
with L-CS-g-PNIPAM-PTX prolonged the survival period of
MDA-MB-231 tumor-bearing mice to a much greater extent
than that in the other groups (Figure 5(C)). Thus, L-CS-g-
PNIPAM-PTX NPs exhibited excellent targeting ability and
effective treatment of MDA-MB-231 human mammary carcin-
oma in vivo, showed high treatment efficacy and significantly
reduced systemic toxicity.
Figure 4. (A) In vitro PTX release in PBS at different pH and different temperatures, as measured by a dialysis method. The increase of PTX concentration was deter-
mined by HPLC (n¼ 3). (B) Hemolytic activity of free PTX, L-CS-g-PNIPAM and L-CS-g-PNIPAM-PTX NPs on mice red blood cells (n¼ 3, mean ± SD).
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Histological analyses of tumor apoptosis
The histological analyses of tumor growth inhibition by this
NPs, TUNEL apoptosis assay, and H&E staining were per-
formed. TUNEL assays revealed that L-CS-g-PNIPAM-PTX NPs
induced wide spread apoptosis of tumor cells, on the other
hand, nearly no cell apoptosis (claybank dots) was observed
in groups treated with saline, and few of TUNEL positive sites
were found in groups treated with free PTX, suggesting that
this system could inhibit tumor growth through inducing
cells apoptosis in solid tumor (Figure 5(D)(a–c)). The similar
tendency was also observed in H&E staining assay (Figure
5(D)(d–f)). The results of H&E staining showed that L-CS-g-
PNIPAM-PTX NPs caused severe necrosis in the tumor tissue.
On the contrary, less tumor cell death was observed for mice
treated with saline or free PTX. Figure 5(E) shows the
quantitative analysis of the TUNEL-positive and cell apoptosis
in each group, and it can be seen that L-CS-g-PNIPAM-PTX
NPs induced significant cell apoptosis in the tumor tissue.
These results confirm that L-CS-g-PNIPAM-PTX NPs could
effectively target to GRP78 positive human breast tumor
xenografts, kill cancer cells by both apoptosis and necro-
sis mechanisms.
Conclusions
In summary, a thermally responsive PNIPAM has been grafted
onto the CS via a facile RAFT process and the CS-g-PNIPAM
copolymer conjugate self-assembles into nano-spheres with
a favorable size distribution and smart stimuli-responsive
drug release profiles that are highly desired for intravenous
Figure 5. In vivo tumor therapy characterization: (A) tumor growth after systemic administration of different drug treatments to mice bearing MDA-MB-231
(mean± SD, n¼ 10); (B) in vivo toxicity (in terms of body weight lost) of saline (control), free PTX, and L-CS-g-PNIPAM-PTX on mice bearing MDA-MB-231 tumors
after a schedule of multiple doses; (C) Kaplan–Meier’s survival curve of tumor-bearing mice after different treatments. (D) Representative photomicrographs of
tumors with TUNEL (a–c), as well as H&E staining of tumor sections (d–f); (E) quantitative analysis of TUNEL-positive and cell apoptosis in each group (mean± SD,
n¼ 10), p< .05, compared with saline group; p< .01, compared with saline group.
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administration. Moreover, L-peptide coated with PTX loaded
CS-g-PNIPAM NPs can induce potent antitumor effects via
both intra-tumor and systemic administration. Furthermore,
L-CS-g-PNIPAM-PTX NPs achieved greater cancer cell killing
efficacy than free PTX, establishing that this formulation can
further enhance the synergistic therapeutic effect of a com-
bination treatment. These results were reproduced in vivo,
where L-CS-g-PNIPAM-PTX NPs induced an antitumor effect
by enhancing the accumulation of oncolytic drug and induc-
tion of apoptosis in tumor tissue. Taken together, the use of
L-CS-g-PNIPAM-PTX NPs is a promising strategy for inducing
systemic antitumor effects in future breast cancer clin-
ical trials.
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